Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

amiloride Articles

New Zealand consults on amiloride, perindopril and trandolapril funding

11 March 2013

Goldshield acquires three product licenses from Novartis for L6.5m

6 April 2000

Results To June 30 See Losses For Smaller US Firms

21 August 1995

IMPACT OF SWEDISH REFERENCE PRICING PLAN

6 June 1994

CYSTIC FIBROSIS; WHAT COMES AFTER PULMOZYME?

7 March 1994

R-PR LAUNCHES THERAPLIX DIVISION

21 February 1994

IMPACT OF SWEDISH REFERENCE PRICING

10 January 1994

MSD CUTS UK PRICES

4 October 1993

US RESEARCH INTO CYSTIC FIBROSIS

12 July 1993

GLAXO'S AMILORIDE IN PHASE III

8 June 1992

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS